Sequanta chooses Olink® Explore 3072 to analyze a new cohort study in China
UPPSALA, Sweden, Jan. 20, 2022 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq:OLK) today announced that Sequanta Technologies, a leading China-based multi-omics service provider, will use Olink® Explore 3072 to analyze 1,000 patient samples from a new cohort study in China.
Since 2021, the partnership between Sequanta and Olink has provided Sequanta with access to Olink’s Proximity Extension Assay (PEA) technology. This collaboration has enabled end-to-end multi-omics clinical studies, which could also facilitate the development of precision medicine in China. As Olink’s preferred third-party service provider in China, Sequanta serves pharmaceutical and academic customers in this geography, utilizing Olink’s innovative and disruptive technology, particularly in high-throughput multi-omics research based on genomics, transcriptomics and proteomics.
“We have seen strong local demand over the past year, demonstrated by clear market interest and the significant number of contracts Sequanta has signed with prestigious research institutions and biopharmaceutical companies,” said Lele Sun, PhD, Founder and CEO of Sequanta. “In this new program, Sequanta will use the Olink tool® Explore the 3072 high-throughput proteomics platform to analyze more than 1,000 human samples from a large-scale cohort study for the study of new markers and therapeutic targets in common chronic diseases in collaboration with one of the best universities in china.
“After years of customer requests for Olink’s pioneering technology, we are very pleased to also see growing demand from our customers in China in expanding our protein biomarker library with Olink.® Explore 3072,” said Andrea Ballagi, MD, PhD, Vice President Sales and Marketing Asia and Pacific Region, Olink Proteomics. “The rapidly growing field of proteomics is expected to play an increasingly important role in human health, and we look forward to working with Sequanta to meet the needs of this market.
Jan Medina, CFA, Vice President of Investor Relations and Capital Markets, Olink
Mobile: +1 617 802 4157
Andrea Prander, Corporate Communications Manager, Olink
Mobile: +46 768 775 275
Olink Holding AB (Nasdaq:OLK) is a company dedicated to accelerating proteomics in collaboration with the scientific community, in multiple disease areas, to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services that are deployed across leading pharmaceutical companies and leading clinical and academic institutions to deepen understanding of human biology in real time and drive 21st century healthcare through science. actionable and impactful. The company was founded in 2016 and is well established in Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
Sequanta Technologies is a leading multi-omics clinical and research service provider in China, focusing on genomics, proteomics and related services to support pharmaceutical customers in biomarker discovery and clinical trials. Sequanta provides diverse genomics and proteomics assays validated by research standard and CAP standard, which include genotyping and gene expression qPCR assays, NGS assays, and protein biomarker detection assays. Tests featured include Foundation One CDx, Illumina TSO500 Tissue and ctDNA Assay, 10x Genomics Single Cell Solution, Olink Target 96 QPCR, Olink Explore Panel 384/1536/3072 on NovaSeq, NGS Meta-Genome, mRNA sequencing, smRNA sequencing, whole genome sequencing, exome sequencing, etc. Custom panels are also available based on specific project needs.
This release may contain forward-looking statements within the meaning of applicable securities laws, including the United States Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding strategy, business plans and direction of Olink. The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimates’, ‘predicts’, ‘project’, ‘potential’, ‘pursue’, ‘target’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of important risks, uncertainties and factors that may cause actual events or results differ materially from those expressed or implied. by any forward-looking statements contained in this press release, including, without limitation, those relating to Olink’s business, operations, supply chain, strategy, objectives and anticipated timelines, including including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition and other risks identified in the section titled “Risk Factors” in Olink’s registration statement on Form F- 1, as amended (File No. 333-253818) filed with the United States Securities and Exchange Commission (SEC) and in the other filings, reports and documents that Olink files from time to time with the SEC. Olink expressly disclaims any obligation to update any forward-looking statements contained in this release to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which such statement is based, except as required by law or regulations require it.